Estimación de las proyecciones del cáncer de vejiga en España

Bernal-Pérez, María C.; Souza, Dyego Leandro Bezerra de; Romero-Fernández, F.J.; Gómez-Bernal, G.; Gomez-Bernal, Federico

doi:10.1016/j.acuro.2012.07.007

Cited by 9 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From 1993 to 2007, rates of BC increased for both men and women; however, mortality rates for men remained stable [24,28,37,38], while a slight decrease was recorded for women [38,39]. The projections derived from these data [27] predicted a decrease in rates of BC incidence and mortality for men and an increase in both rates for women. However, these projections have not been analysed, and there have been no studies that investigated BC mortality trends in Spain over the last 15 years.…”

Section: Introductionmentioning

confidence: 97%

“…In terms of mortality, BC is the second highest cause of death from urological tumours (behind prostate cancer) and is responsible for at least 165,000 deaths/year worldwide [23,26]. In Spain, the crude mortality rate is 12/100,000, with significant differences in terms of gender comparison [27]. In women, the age-adjusted mortality rate (AAMR) is 1.08/100,000 (which is the European average) compared to 8.1/100,000 in men, which is one of the highest rates in Europe [24,28,29].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mortality Trends Related to Bladder Cancer in Spain, 1999–2018

Sanz

Martínez-Cayuelas

Gil-Guillén

et al. 2022

JCM

View full text Add to dashboard Cite

Bladder cancer (BC) is an important cause of premature mortality (PM, <75 years). Spain has one of the highest BC mortality rates in Europe. The objective of this study was to analyse BC mortality trends between 1999 and 2018 in Spain. The study was based on data from the National Institute of Statistics (Instituto Nacional de Estadística—INE). Age-adjusted mortality rates (AAMRs) were calculated by sex and age group. A trend analysis was performed using Joinpoint regression models and years of potential life lost (YPLL). Mortality in men resulting from BC decreased in all age groups studied. This was not observed in women, for whom mortality only decreased in the ≥75 age group. Deaths due to BC occurred prematurely in 38.6% of men and in 23.8% of women, which indicated a greater impact on YPLL in men compared to women. Over the last 20 years, there has been a significant decrease in BC mortality rate, except in women under 75 years of age. Despite this temporal trend of decreasing mortality, BC continues to have a significant impact on YPLL, mainly in men. Given this context, it is important to direct more resources towards prevention and early diagnosis strategies to correct this situation.

show abstract

Section: Introductionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Mortality Trends Related to Bladder Cancer in Spain, 1999–2018

Sanz

Martínez-Cayuelas

Gil-Guillén

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…In Spain, the crude mortality rate is 12/100,000, with significant differences in terms of gender comparison. In men, this mortality rate is 8.1 per 100,000, which is one of the highest in Europe [4,5].…”

Section: Introductionmentioning

confidence: 98%

Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?

Lozano

Raventós

Carrión

et al. 2023

Cancers

View full text Add to dashboard Cite

XBM was prospectively assessed in spontaneous urine collected just before flexible cystoscopy and washing cytology carried out within the first 2 years follow-up of 337 patients with NMIBC. Recurrences were pathologically confirmed in 49 patients (14.5%), 22 of them being high-risk (6.5%). The XBM sensitivity for detecting any type of recurrence was 69.4% and 63.6% in the cases of high-risk NMIBC. Negative predictive value (NPV) for XBM was 93% for all recurrences and 96.2% for high-risk recurrences. XBM could have avoided 213 invasive controls but missed the detection of 15 recurrences (30.6%)–8 of them of high-risk (36.4%). XBM false positive elevations were detected in 90 patients (26.7%), whereas 10 patients with the invasive method had a false positive result (3%), p <0.001. However, early detection of recurrences during the first year’s follow-up after an XBM false positive result was observed in 18 patients (20%). On the other hand, 19 recurrences were detected during this period among the rest of the patients (7.7%)—p = 0.003, and odds ratio (OR) 3.0 (95% CI 1.5–6.0). Regarding one-year follow-up recurrences, 10% were high-risk recurrences in the XBM false positive group and 3.2% in the rest of the patients—p = 0.021, and OR 3.3 (95% CI 1.2–8.9). Additionally, 11.3% of the patients without false positive results developed a recurrence, p = 0.897, for any recurrence, being 10% and 5.2%, respectively, and high-risk and low-risk recurrences, p = 0.506. After searching for the best XBM cutoff for detecting the 38 high-risk initial recurrences and the early high-risk recurrences after a one-year follow-up, a linear discriminant analysis (LDA) of 0.13 could have avoided 11.3% of cystoscopies and bladder wash cytologies, as this cutoff missed only 1 high-risk recurrence (2.6%). More extensive and well-designed studies will confirm if XBM can improve the surveillance of NMIBC.

show abstract

“…2 The trend of this tumor in our country is different according to sex, so both the incidence and mortality decrease in men, and they both increase in the case of women, very likely associated with the evolution of tobacco consumption in both sexes. 7 In terms of geographic variability, it is defined mainly by the prevalence of smokers, 6 although geographical areas are observed (Cádiz, Seville, Huelva, Almería, and Barcelona) where excess risk is not only attributable to smoking but also to where water quality for human consumption, and especially arsenic, could be involved in this excess risk. 8 Therefore, this study aims to determine the incidence, trends, and geographical distribution of bladder cancer in an area of high incidence.…”

Section: Introductionmentioning

confidence: 99%